A study led by Weill Cornell Medicine researchers found that EZH2 inhibitors, a new class of anticancer drugs, could enhance the potency of cancer immunotherapies for non-Hodgkin B-cell lymphomas. The inhibitors target the EZH2 enzyme, known to be a significant factor in many cancers. Combining EZH2 inhibition with T-cell based immunotherapy was found to be more effective at shrinking lymphomas than immunotherapy alone. Preclinical trials have shown promising results with the combination of EZH2 inhibitors and T-cell immunotherapies, potentially improving the potency and durability of these treatments. This research could lead to new therapeutic targets for lymphoma patients.
Source link
EZH2 inhibitors enhance effectiveness of cancer immunotherapies
